KR102489475B1 - 결합 단백질 및 그의 사용 방법 - Google Patents

결합 단백질 및 그의 사용 방법 Download PDF

Info

Publication number
KR102489475B1
KR102489475B1 KR1020167022746A KR20167022746A KR102489475B1 KR 102489475 B1 KR102489475 B1 KR 102489475B1 KR 1020167022746 A KR1020167022746 A KR 1020167022746A KR 20167022746 A KR20167022746 A KR 20167022746A KR 102489475 B1 KR102489475 B1 KR 102489475B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167022746A
Other languages
English (en)
Korean (ko)
Other versions
KR20160125381A (ko
Inventor
칼야니 몬달
베티 찬 리
유 첸
따루나 아로라
휴고 마턴
원냔 센
Original Assignee
엔지엠 바이오파마슈티컬스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔지엠 바이오파마슈티컬스, 아이엔씨. filed Critical 엔지엠 바이오파마슈티컬스, 아이엔씨.
Publication of KR20160125381A publication Critical patent/KR20160125381A/ko
Application granted granted Critical
Publication of KR102489475B1 publication Critical patent/KR102489475B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020167022746A 2014-01-24 2015-01-23 결합 단백질 및 그의 사용 방법 Active KR102489475B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931531P 2014-01-24 2014-01-24
US61/931,531 2014-01-24
PCT/US2015/012731 WO2015112886A2 (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20160125381A KR20160125381A (ko) 2016-10-31
KR102489475B1 true KR102489475B1 (ko) 2023-01-20

Family

ID=53678415

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167022746A Active KR102489475B1 (ko) 2014-01-24 2015-01-23 결합 단백질 및 그의 사용 방법

Country Status (29)

Country Link
US (5) US9738716B2 (enExample)
EP (2) EP3097122B9 (enExample)
JP (3) JP6837840B2 (enExample)
KR (1) KR102489475B1 (enExample)
CN (1) CN106662577B (enExample)
AU (1) AU2015209131B2 (enExample)
CA (1) CA2937898C (enExample)
CL (1) CL2016001868A1 (enExample)
CY (1) CY1123163T1 (enExample)
DK (1) DK3097122T3 (enExample)
ES (1) ES2808340T3 (enExample)
HR (1) HRP20200881T1 (enExample)
HU (1) HUE050279T2 (enExample)
IL (1) IL246921B (enExample)
LT (1) LT3097122T (enExample)
MX (1) MX375032B (enExample)
MY (1) MY191944A (enExample)
NZ (1) NZ722377A (enExample)
PE (1) PE20170256A1 (enExample)
PH (1) PH12016501644B1 (enExample)
PL (1) PL3097122T3 (enExample)
PT (1) PT3097122T (enExample)
RS (1) RS60593B1 (enExample)
RU (1) RU2701434C2 (enExample)
SG (2) SG11201606018UA (enExample)
SI (1) SI3097122T1 (enExample)
UA (1) UA119863C2 (enExample)
WO (1) WO2015112886A2 (enExample)
ZA (1) ZA201605151B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10293026B2 (en) 2014-09-08 2019-05-21 Osaka University Agent for preventing or treating demyelinating disease
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR102728071B1 (ko) 2015-08-03 2024-11-11 노파르티스 아게 Fgf21-연관 장애를 치료하는 방법
CN116474091A (zh) 2015-08-24 2023-07-25 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
MX2018003536A (es) 2015-09-24 2018-08-01 Genentech Inc Metodos para el tratamiento de la epilepsia.
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3004804A1 (en) * 2015-11-17 2017-05-26 Jiangsu Hengrui Medicine Co., Ltd. Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
US20240076332A1 (en) * 2016-10-04 2024-03-07 Svar Life Science Ab FGF21 Responsive Reporter Gene Cell Line
JP6991246B2 (ja) 2017-02-08 2022-02-03 ノバルティス アーゲー Ｆｇｆ２１模倣抗体及びその使用
CA3076396A1 (en) * 2017-09-20 2019-03-28 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
CN120267815A (zh) 2018-09-10 2025-07-08 冷泉港实验室 用于治疗胰腺炎的方法
KR20200123754A (ko) * 2019-04-22 2020-10-30 연세대학교 산학협력단 클로토 단백질 또는 이를 암호화하는 유전자를 유효성분으로 포함하는 조성물
CN110616195B (zh) * 2019-10-11 2021-05-04 江南大学 一株二甲双胍单克隆抗体杂交瘤细胞株及其应用
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
US12054551B2 (en) * 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
JP2023535073A (ja) * 2020-07-23 2023-08-15 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
TW202307007A (zh) 2021-05-04 2023-02-16 美商再生元醫藥公司 多特異性fgf21受體促效劑及其等用途
US20240269285A1 (en) * 2021-06-30 2024-08-15 Board Of Regents, The University Of Texas System Polypeptides targeting cd70-positive cancers
CN117813323A (zh) * 2021-09-23 2024-04-02 江苏恒瑞医药股份有限公司 抗klb抗体及用途
JP2025502820A (ja) * 2021-12-30 2025-01-28 上▲海▼津曼特生物科技有限公司 抗βＫｌｏｔｈｏ抗体およびその使用
CN115197300B (zh) * 2022-05-17 2023-05-05 四川大学华西第二医院 一种对rna具有非序列特异性且高度亲和力的蛋白及其应用
CN118406147B (zh) * 2022-08-02 2025-04-08 东莞市朋志生物科技有限公司 抗b型尿钠肽抗体或其功能性片段、检测b型尿钠肽的试剂和试剂盒
CN116120442B (zh) * 2023-01-30 2025-10-17 深圳市第三人民医院 一种广谱中和SARS-CoV-2的中和抗体P2-1B1及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135657A1 (en) * 2009-12-07 2011-06-09 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
US20120328616A1 (en) * 2011-06-06 2012-12-27 Amgen Inc. Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
ATE238668T1 (de) 1995-01-17 2003-05-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelialer transport von immunogenen
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO1998029544A1 (en) 1996-12-26 1998-07-09 Kyowa Hakko Kogyo Co., Ltd. Novel peptide, novel dna, and novel antibody
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20060246540A1 (en) 1997-08-26 2006-11-02 Ashkenazi Avi J Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20030044839A1 (en) 1997-09-17 2003-03-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030113718A1 (en) 1997-09-17 2003-06-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6806352B2 (en) 1997-09-17 2004-10-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2001516580A (ja) 1997-09-17 2001-10-02 ジェネンテック・インコーポレーテッド 分泌性の、および膜貫通性のポリぺプチド、およびそれをコードする核酸
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US7390879B2 (en) 1999-06-15 2008-06-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7129072B1 (en) 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
JP2001072607A (ja) 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd 新規血管内皮機能改善法
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
DE60043197D1 (enExample) 1999-11-18 2009-12-03 Univ Kyoto
WO2001038529A1 (fr) 1999-11-19 2001-05-31 Kyowa Hakko Kogyo Co., Ltd. Nouveau polypeptide, nouvel adn, nouvel anticorps et nouvel animal transgenique
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
AU2631001A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf11
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
US20010044525A1 (en) 2000-01-05 2001-11-22 Conklin Darrell C. Novel FGF Homolog zFGF12
CA2396401A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
JP2005508131A (ja) 2000-02-15 2005-03-31 アムジェン インコーポレイテッド 線維芽細胞成長因子−２３分子およびその使用
US20060160181A1 (en) 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20030180312A1 (en) 2000-02-22 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030105302A1 (en) 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
EP1261638A2 (en) 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
ES2340662T3 (es) 2000-07-19 2010-06-08 Advanced Research And Technology Institute Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7537902B2 (en) 2000-10-24 2009-05-26 Emory University Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20030045489A1 (en) 2000-11-22 2003-03-06 Murphy John E. Methods for modulating angiogenesis
US20020151496A1 (en) 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
DE10100588A1 (de) 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
DE10100587C1 (de) 2001-01-09 2002-11-21 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ES2405551T3 (es) 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
JP2003334088A (ja) 2002-05-22 2003-11-25 Pharma Design Inc ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) 2002-06-07 2007-08-08 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
AU2003268116A1 (en) 2002-09-18 2004-04-08 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
JP2006240990A (ja) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
ES2298785T3 (es) 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CA2549249A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
US7576190B2 (en) 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins
JP2006016323A (ja) 2004-06-30 2006-01-19 Hiroshima Industrial Promotion Organization 生理活性バイオマテリアル
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
ATE444307T1 (de) 2004-09-02 2009-10-15 Lilly Co Eli Muteine des fibroblasten-wachstumsfaktors 21
EP1817335A2 (en) 2004-10-29 2007-08-15 Genentech, Inc. Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
AU2005300688B2 (en) 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
JP2006158339A (ja) 2004-12-09 2006-06-22 Kyoto Univ βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090081658A1 (en) 2005-08-24 2009-03-26 Abdelmajid Belouchi Genemap of the human genes associated with crohn's disease
CA2637216A1 (en) 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
WO2008021196A2 (en) 2006-08-09 2008-02-21 The Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
CN101563597A (zh) 2006-09-01 2009-10-21 美国菌种保藏中心 用于诊断和治疗2型糖尿病的组合物和方法
WO2008052796A1 (en) 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
EP2115125B1 (en) 2007-01-03 2016-09-07 NeoStem Oncology, LLC Stem cell growth media and methods of making and using same
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
LT2550972T (lt) 2007-04-02 2018-05-10 Genentech, Inc. Kloto-beta agonistinis antikūnas, skirtas cukrinio diabeto arba atsparumo insulinui gydymui
JP5187837B2 (ja) 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
US7537903B2 (en) * 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
US10555963B2 (en) 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
WO2008135993A1 (en) 2007-05-08 2008-11-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
US20120142546A1 (en) 2007-12-10 2012-06-07 The Johns Hopkins University Hypomethylated genes in cancer
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20090226459A1 (en) 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
NZ579566A (en) 2008-03-19 2013-01-25 Ambrx Inc Modified fgf-21 polypeptides and their uses
AU2009226246A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
US20100274362A1 (en) 2009-01-15 2010-10-28 Avner Yayon Cartilage particle tissue mixtures optionally combined with a cancellous construct
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2010139741A1 (en) 2009-06-04 2010-12-09 Novartis Ag Fgf-21 for treating cancers
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
KR101952453B1 (ko) 2009-10-15 2019-02-26 제넨테크, 인크. 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
EP2558115B1 (en) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
EP2613773A2 (en) 2010-09-09 2013-07-17 Trifoilium ApS Airway administration of angiogenesis inhibitors
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102464712A (zh) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 缺失型人成纤维细胞生长因子21变异体及其偶联物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
WO2012086809A1 (ja) 2010-12-24 2012-06-28 独立行政法人産業技術総合研究所 ヒトfgf19活性の正確で高感度な測定方法ならびにヒトfgf19活性の制御剤
MX343729B (es) 2011-04-08 2016-11-18 Amgen Inc Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
CA2835101A1 (en) 2011-05-10 2012-11-15 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and .beta.-klotho
DK2710035T3 (en) 2011-05-16 2017-06-19 Hoffmann La Roche FGFR1 agonists and methods of use
EP2718486A4 (en) 2011-06-08 2014-12-31 Denovo Biopharma Hangzhou Ltd Co METHODS AND COMPOSITIONS FOR PREDICTING THE ACTIVITY OF A RETINOID RECEPTOR X MODULATOR
EP2723391B1 (en) 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
EP2750695A2 (en) 2011-08-31 2014-07-09 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
HK1201851A1 (en) 2011-11-11 2015-09-11 瑞纳神经科学公司 Antibodies specific for trop-2 and their uses
BR112014017626A2 (pt) 2012-01-18 2018-05-22 Genentech Inc métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
JP2013194049A (ja) 2012-03-23 2013-09-30 Kazuo Todokoro ヒト造血幹細胞を増幅させるための組成物及び方法
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
WO2013156920A1 (en) 2012-04-16 2013-10-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho variant polypeptides and uses thereof in therapy
EA201491856A1 (ru) 2012-05-15 2015-03-31 Эли Лилли Энд Компани Терапевтическое применение белков фактора роста фибробластов 21
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CN104364261B (zh) 2012-06-11 2017-04-05 伊莱利利公司 成纤维细胞生长因子21变体
US8802697B2 (en) 2012-07-11 2014-08-12 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
JP2015533483A (ja) 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014152090A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
WO2018044778A1 (en) 2016-08-29 2018-03-08 NGM Biopharmaceuticals, Inc Methods for treatment of bile acid-related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135657A1 (en) * 2009-12-07 2011-06-09 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
US20120328616A1 (en) * 2011-06-06 2012-12-27 Amgen Inc. Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

Also Published As

Publication number Publication date
EP3097122A2 (en) 2016-11-30
LT3097122T (lt) 2020-07-27
CY1123163T1 (el) 2021-10-29
US12378312B2 (en) 2025-08-05
JP2017507652A (ja) 2017-03-23
MX2016009555A (es) 2016-12-08
PH12016501644B1 (en) 2021-10-06
NZ722377A (en) 2022-09-30
US20190106490A1 (en) 2019-04-11
ZA201605151B (en) 2020-12-23
BR112016017248A2 (pt) 2017-10-03
CN106662577A (zh) 2017-05-10
BR112016017248A8 (pt) 2018-04-17
MY191944A (en) 2022-07-20
WO2015112886A2 (en) 2015-07-30
CL2016001868A1 (es) 2017-07-21
SI3097122T1 (sl) 2020-07-31
CA2937898C (en) 2025-05-06
SG11201606018UA (en) 2016-08-30
JP7436571B2 (ja) 2024-02-21
KR20160125381A (ko) 2016-10-31
JP2020169173A (ja) 2020-10-15
RU2701434C2 (ru) 2019-09-26
HUE050279T2 (hu) 2020-11-30
EP3097122B9 (en) 2020-11-11
US11596676B2 (en) 2023-03-07
IL246921A0 (en) 2016-09-29
US10744191B2 (en) 2020-08-18
AU2015209131A1 (en) 2016-08-11
US20150210764A1 (en) 2015-07-30
ES2808340T3 (es) 2021-02-26
RS60593B1 (sr) 2020-08-31
CA2937898A1 (en) 2015-07-30
MX375032B (es) 2025-03-06
US9738716B2 (en) 2017-08-22
EP3738981A1 (en) 2020-11-18
US20180100014A1 (en) 2018-04-12
PH12016501644A1 (en) 2016-11-07
EP3097122B1 (en) 2020-05-06
PL3097122T3 (pl) 2020-10-19
RU2016130128A3 (enExample) 2018-09-04
UA119863C2 (uk) 2019-08-27
US10093735B2 (en) 2018-10-09
HRP20200881T1 (hr) 2020-09-04
US20230256070A1 (en) 2023-08-17
JP2022153375A (ja) 2022-10-12
JP6837840B2 (ja) 2021-03-10
PT3097122T (pt) 2020-07-21
EP3097122A4 (en) 2017-09-20
RU2016130128A (ru) 2018-02-27
CN106662577B (zh) 2020-07-21
DK3097122T3 (da) 2020-08-10
SG10201806108TA (en) 2018-08-30
AU2015209131B2 (en) 2020-06-25
ES2808340T9 (es) 2021-03-05
US20210030857A1 (en) 2021-02-04
WO2015112886A3 (en) 2015-10-01
IL246921B (en) 2019-09-26
PE20170256A1 (es) 2017-04-22

Similar Documents

Publication Publication Date Title
KR102489475B1 (ko) 결합 단백질 및 그의 사용 방법
US12180289B2 (en) Binding proteins and methods of use thereof
US11667708B2 (en) Anti-human beta klotho antibody or binding fragment thereof and methods of their use
HK40036377A (en) Antibodies binding beta klotho domain 2 and methods of use thereof
RU2786909C2 (ru) Связывающие белки и способы их применения
HK1229825A1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825B (en) Antibodies binding beta klotho domain 2 and methods of use thereof
BR112016017248B1 (pt) Anticorpo, célula hospedeira, composição farmacêutica e uso do anticorpo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601